Background HFDs have adverse effects on metabolic health, which puts individuals at risk of obesity and liver and kidney dysfunction. Orlistat is an antihypertensive agent against obesity that prevents the absorption of dietary fats, although its impact on hepatic and renal functions is still disputed. In this study, the dose-dependent effects of orlistat on liver and renal functioning were in male rats on an HFD were assessed. Methods There was a control HFD group and three HFD groups with orlistat (360, 480 and 600 mg/kg) on male rats over 60 days. Lipid profiles, liver enzymes (AST, ALT, GGT, ALP), kidney (urea, creatinine, direct and indirect bilirubin), and hematological (hemoglobin, hematocrit, RBC, WBC counts, MCV, MCH, MCHC) serum tests were done. Histopathological analysis of liver and kidney tissues was done. Findings Orlistat caused dose-related changes in lipid profiles, increased liver enzymes, and an increased mark of kidney functioning. The hematological parameters were also greatly impaired, and the histopathology indicated structural and tissue damage in both of the organs, more so at higher doses. Conclusions Orlistat was used in HFD-conditions in male rats, which resulted in severe dose-related impairment of the liver and kidney. These results highlight the importance of close observation of hepatic and renal functions when using orlistat especially in the high-fat dietary situation.
Alkadhimy et al. (2026) studied this question.